Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Multiparameter MRI quantification of microstructural tissue alterations in multiple sclerosis.

Lommers E, Simon J, Reuter G, Delrue G, Dive D, Degueldre C, Balteau E, Phillips C, Maquet P.

Neuroimage Clin. 2019;23:101879. doi: 10.1016/j.nicl.2019.101879. Epub 2019 May 29.

2.

[Indications and follow-up for autologous hematopoietic stem cell transplantation in multiple sclerosis: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) in association with the Francophone Society of Multiple Sclerosis].

Zephir H, Puyade M, Gueguen A, Michel L, Terriou L, Dive D, Laureys G, Mathey G, Labauge P, Marjanovic Z, Pugnet G, Badoglio M, Lansiaux P, Yakoub-Agha I, Béguin Y, Farge D.

Bull Cancer. 2019 Jan;106(1S):S92-S101. doi: 10.1016/j.bulcan.2018.11.002. Epub 2018 Dec 5. French.

3.

NMOSD with anti-MOG antibodies following anti-TNFα therapy: A case report.

Lommers E, Depierreux F, Hansen I, Dive D, Maquet P.

Mult Scler Relat Disord. 2018 Nov;26:37-39. doi: 10.1016/j.msard.2018.08.029. Epub 2018 Aug 31.

PMID:
30219743
4.

Is the triple stimulation technique a better quantification tool of motor dysfunction than motor evoked potentials in multiple sclerosis?

Giffroy X, Dive D, Kaux JF, Maes N, Albert A, Göbels C, Wang F.

Acta Neurol Belg. 2019 Mar;119(1):47-54. doi: 10.1007/s13760-018-1001-1. Epub 2018 Aug 22.

PMID:
30136146
5.

A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis.

Laureys G, Willekens B, Vanopdenbosch L, Deryck O, Selleslag D, D'Haeseleer M, De Becker A, Dubois B, Dierickx D, Perrotta G, De Wilde V, van Pesch V, Straetmans N, Dive D, Beguin Y, Van Wijmeersch B, Theunissen K, Kerre T, Van de Velde A.

Acta Neurol Belg. 2018 Jun;118(2):161-168. doi: 10.1007/s13760-018-0905-0. Epub 2018 Mar 13.

6.

Correction to: Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus.

Lambert C, Dubois B, Dive D, Lysandropoulos A, Selleslag D, Vanopdenbosch L, Van Pesch V, Vanwijmeersch B, Janssens A.

Acta Neurol Belg. 2018 Mar;118(1):141. doi: 10.1007/s13760-018-0899-7.

PMID:
29500681
7.

Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus.

Lambert C, Dubois B, Dive D, Lysandropoulos A, Selleslag D, Vanopdenbosch L, Van Pesch V, Vanwijmeersch B, Janssens A.

Acta Neurol Belg. 2018 Mar;118(1):7-11. doi: 10.1007/s13760-018-0882-3. Epub 2018 Jan 27. Erratum in: Acta Neurol Belg. 2018 Mar 3;:.

8.

Management of adverse renal events related to alemtuzumab treatment in multiple sclerosis: a Belgian consensus.

Sprangers B, Decoo D, Dive D, Lysandropoulos A, Vanopdenbosch L, Bovy C.

Acta Neurol Belg. 2018 Jun;118(2):143-151. doi: 10.1007/s13760-017-0864-x. Epub 2017 Nov 30.

9.

Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it?

Rouzaud C, Hautecoeur P, Donze C, Heinzlef O, Dinh A; Club Francophone de la Sclérose en Plaque, Creange A, Abdullatif A, Audouin B, Tourbah A, Berger E, Bourre B, Brochet B, Mekies C, Cabre P, Papeix C, Casez O, Brassat D, Defer G, Derache N, De Seze J, Dive D, LePage E, Fromont A, Gouider R, Edan G, Pelletier J, Grimaud J, Guennoc AM, Camdessanché JP, Kwiatkowski A, Laplaud D, Lebrun C, Debouverie M, Coustans M, Gout O, La Rochelle OA, Heinzlef O, Ouallet JC, Cavelou P, Hautecoeur P, Labauge P, Vermersch P, Wiertlewski S, Vukusic S, Marignier R, Schluep M, Seeldrayers P, Slassi I, Stankoff B, Thaite F, Moreau T, Thouvenot E, Zephir H, Ciron J, Collongues N, Kerschen P, Cohen M, Gueguen A, Mathey G, Carra C, Bernady P, Faucheux JM, Planque E, Donze C, Ruet A, Mouzawakh C, Pittion S.

Mult Scler Relat Disord. 2017 Nov;18:161-163. doi: 10.1016/j.msard.2017.08.009. Epub 2017 Aug 24. No abstract available.

PMID:
29141801
10.

Corticosteroids in the management of acute multiple sclerosis exacerbations.

Smets I, Van Deun L, Bohyn C, van Pesch V, Vanopdenbosch L, Dive D, Bissay V, Dubois B; Belgian Study Group for Multiple Sclerosis.

Acta Neurol Belg. 2017 Sep;117(3):623-633. doi: 10.1007/s13760-017-0772-0. Epub 2017 Apr 8. Review.

PMID:
28391390
11.

Multimodal evoked potentials for functional quantification and prognosis in multiple sclerosis.

Giffroy X, Maes N, Albert A, Maquet P, Crielaard JM, Dive D.

BMC Neurol. 2016 Jun 1;16:83. doi: 10.1186/s12883-016-0608-1.

12.

Do evoked potentials contribute to the functional follow-up and clinical prognosis of multiple sclerosis?

Giffroy X, Maes N, Albert A, Maquet P, Crielaard JM, Dive D.

Acta Neurol Belg. 2017 Mar;117(1):53-59. doi: 10.1007/s13760-016-0650-1. Epub 2016 May 19.

PMID:
27194163
13.

Ferroquine as an oxidative shock antimalarial.

Dive D, Biot C.

Curr Top Med Chem. 2014;14(14):1684-92.

PMID:
25116581
14.

[Is this cerebral cavernoma the cause of a Parkinsonian syndrome?].

Benmouna K, Dive D, Wang F, Martin D, Crielaard JM, Kaux JF.

Rev Med Liege. 2013 Dec;68(12):613-6. French.

15.

The ferroquine antimalarial conundrum: redox activation and reinvasion inhibition.

Dubar F, Slomianny C, Khalife J, Dive D, Kalamou H, Guérardel Y, Grellier P, Biot C.

Angew Chem Int Ed Engl. 2013 Jul 22;52(30):7690-3. doi: 10.1002/anie.201303690. Epub 2013 Jun 13.

PMID:
23765846
16.

Deciphering the Resistance-Counteracting Functions of Ferroquine in Plasmodium falciparum-Infected Erythrocytes.

Dubar F, Bohic S, Dive D, Guérardel Y, Cloetens P, Khalife J, Biot C.

ACS Med Chem Lett. 2012 Apr 13;3(6):480-3. doi: 10.1021/ml300062q. eCollection 2012 Jun 14.

17.

Partial trisomy 4q associated with young-onset dopa-responsive parkinsonism.

Garraux G, Caberg JH, Vanbellinghen JF, Jamar M, Bours V, Moonen G, Dive D.

Arch Neurol. 2012 Mar;69(3):398-400. doi: 10.1001/archneurol.2011.802.

PMID:
22410449
18.

The antimalarial ferroquine: from bench to clinic.

Biot C, Nosten F, Fraisse L, Ter-Minassian D, Khalife J, Dive D.

Parasite. 2011 Aug;18(3):207-14. Review.

19.

[Dorsal Septic metastasis of the initial retropharyngeal abscess responsible for a tétraparésie].

Kaux JF, Lenelle J, Frippiat F, Le Goff C, Bartsch V, Crielaard JM, Dive D.

Rev Neurol (Paris). 2011 Aug-Sep;167(8-9):638-40. doi: 10.1016/j.neurol.2011.03.001. Epub 2011 Apr 15. French. No abstract available.

20.

The antimalarial ferroquine: role of the metal and intramolecular hydrogen bond in activity and resistance.

Dubar F, Egan TJ, Pradines B, Kuter D, Ncokazi KK, Forge D, Paul JF, Pierrot C, Kalamou H, Khalife J, Buisine E, Rogier C, Vezin H, Forfar I, Slomianny C, Trivelli X, Kapishnikov S, Leiserowitz L, Dive D, Biot C.

ACS Chem Biol. 2011 Mar 18;6(3):275-87. doi: 10.1021/cb100322v. Epub 2011 Jan 7.

PMID:
21162558
21.

Synthesis and antimalarial activities of rhenium bioorganometallics based on the 4-aminoquinoline structure.

Arancibia R, Dubar F, Pradines B, Forfar I, Dive D, Klahn AH, Biot C.

Bioorg Med Chem. 2010 Nov 15;18(22):8085-91. doi: 10.1016/j.bmc.2010.09.005. Epub 2010 Sep 19.

PMID:
20934349
22.

Plasmodium falciparum dynein light chain 1 interacts with actin/myosin during blood stage development.

Daher W, Pierrot C, Kalamou H, Pinder JC, Margos G, Dive D, Franke-Fayard B, Janse CJ, Khalife J.

J Biol Chem. 2010 Jun 25;285(26):20180-91. doi: 10.1074/jbc.M110.102806. Epub 2010 Apr 26.

23.
24.

Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach.

Dubar F, Anquetin G, Pradines B, Dive D, Khalife J, Biot C.

J Med Chem. 2009 Dec 24;52(24):7954-7. doi: 10.1021/jm901357n.

PMID:
19908867
25.

Systematic structural studies of iron superoxide dismutases from human parasites and a statistical coupling analysis of metal binding specificity.

Bachega JF, Navarro MV, Bleicher L, Bortoleto-Bugs RK, Dive D, Hoffmann P, Viscogliosi E, Garratt RC.

Proteins. 2009 Oct;77(1):26-37. doi: 10.1002/prot.22412.

PMID:
19384994
26.

Antibody response in children infected with Giardia intestinalis before and after treatment with Secnidazole.

Jiménez JC, Pinon A, Dive D, Capron M, Dei-Cas E, Convit J.

Am J Trop Med Hyg. 2009 Jan;80(1):11-5.

PMID:
19141831
27.

Motor neuron disorders: novel electrophysiologic approach (MUFDEC protocol).

Wang FC, Le Forestier N, Gérard P, Willer JC, Meininger V, Dive D, de Noordhout AM, Bouche P.

Suppl Clin Neurophysiol. 2009;60:143-52. No abstract available.

PMID:
20715376
28.

Ferroquine, an ingenious antimalarial drug: thoughts on the mechanism of action.

Dubar F, Khalife J, Brocard J, Dive D, Biot C.

Molecules. 2008 Nov 20;13(11):2900-7. doi: 10.3390/molecules13112900.

29.

Investigation of the redox behavior of ferroquine, a new antimalarial.

Chavain N, Vezin H, Dive D, Touati N, Paul JF, Buisine E, Biot C.

Mol Pharm. 2008 Sep-Oct;5(5):710-6. doi: 10.1021/mp800007x. Epub 2008 Jun 19.

PMID:
18563912
30.

Molecular characterization of iron-containing superoxide dismutases in the heterotrophic dinoflagellate Crypthecodinium cohnii.

Dufernez F, Derelle E, Noël C, Sanciu G, Mantini C, Dive D, Soyer-Gobillard MO, Capron M, Pierce RJ, Wintjens R, Guillebault D, Viscogliosi E.

Protist. 2008 Apr;159(2):223-38. doi: 10.1016/j.protis.2007.11.005. Epub 2008 Feb 13.

PMID:
18276189
31.

Ferrocene conjugates of chloroquine and other antimalarials: the development of ferroquine, a new antimalarial.

Dive D, Biot C.

ChemMedChem. 2008 Mar;3(3):383-91. Review. No abstract available.

PMID:
17806092
32.

Probing the role of the covalent linkage of ferrocene into a chloroquine template.

Biot C, Daher W, Ndiaye CM, Melnyk P, Pradines B, Chavain N, Pellet A, Fraisse L, Pelinski L, Jarry C, Brocard J, Khalife J, Forfar-Bares I, Dive D.

J Med Chem. 2006 Jul 27;49(15):4707-14.

PMID:
16854077
33.

Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities.

Biot C, Daher W, Chavain N, Fandeur T, Khalife J, Dive D, De Clercq E.

J Med Chem. 2006 May 4;49(9):2845-9.

PMID:
16640347
34.

Regulation of protein phosphatase type 1 and cell cycle progression by PfLRR1, a novel leucine-rich repeat protein of the human malaria parasite Plasmodium falciparum.

Daher W, Browaeys E, Pierrot C, Jouin H, Dive D, Meurice E, Dissous C, Capron M, Tomavo S, Doerig C, Cailliau K, Khalife J.

Mol Microbiol. 2006 May;60(3):578-90.

35.

[Image of the month. A case of rapidly progressing leukoencephalopathy in amyloid angiopathy].

Wauters O, Scholtes F, Dive D, Moonen G.

Rev Med Liege. 2006 Jan;61(1):3-4. French. No abstract available.

36.

Assessment of Plasmodium falciparum resistance to ferroquine (SSR97193) in field isolates and in W2 strain under pressure.

Daher W, Biot C, Fandeur T, Jouin H, Pelinski L, Viscogliosi E, Fraisse L, Pradines B, Brocard J, Khalife J, Dive D.

Malar J. 2006 Feb 7;5:11.

37.

In vitro metabolism of ferroquine (SSR97193) in animal and human hepatic models and antimalarial activity of major metabolites on Plasmodium falciparum.

Daher W, Pelinski L, Klieber S, Sadoun F, Meunier V, Bourrié M, Biot C, Guillou F, Fabre G, Brocard J, Fraisse L, Maffrand JP, Khalife J, Dive D.

Drug Metab Dispos. 2006 Apr;34(4):667-82. Epub 2006 Jan 13.

PMID:
16415117
38.

Analysis of immune response patterns in naïve and Plasmodium berghei-infected young rats following a ferroquine treatment.

Pierrot C, Lafitte S, Dive D, Fraisse L, Brocard J, Khalife J.

Int J Parasitol. 2005 Dec;35(14):1601-10. Epub 2005 Aug 24.

PMID:
16140302
39.

[Diabetic peripheral neuropathy].

Dive D, Lievens I, Moonen G, Wang FC.

Rev Med Liege. 2005 May-Jun;60(5-6):490-7. Review. French.

40.

Identification of a mitochondrial superoxide dismutase with an unusual targeting sequence in Plasmodium falciparum.

Sienkiewicz N, Daher W, Dive D, Wrenger C, Viscogliosi E, Wintjens R, Jouin H, Capron M, Müller S, Khalife J.

Mol Biochem Parasitol. 2004 Sep;137(1):121-32.

PMID:
15279958
41.

[Somatosensory evoked potentials: clinical applications in peripheral neuropathies].

Dive D, Giffroy X.

Rev Med Liege. 2004;59 Suppl 1:157-69. Review. French.

42.

Superoxide dismutase in Plasmodium: a current survey.

Dive D, Gratepanche S, Yera H, Bécuwe P, Daher W, Delplace P, Odberg-Ferragut C, Capron M, Khalife J.

Redox Rep. 2003;8(5):265-7. Review. No abstract available.

PMID:
14962361
43.

Double staining of Plasmodium falciparum nucleic acids with hydroethidine and thiazole orange for cell cycle stage analysis by flow cytometry.

Jouin H, Daher W, Khalife J, Ricard I, Puijalon OM, Capron M, Dive D.

Cytometry A. 2004 Jan;57(1):34-8.

44.

Screening of Plasmodium falciparum iron superoxide dismutase inhibitors and accuracy of the SOD-assays.

Soulère L, Delplace P, Davioud-Charvet E, Py S, Sergheraert C, Périé J, Ricard I, Hoffmann P, Dive D.

Bioorg Med Chem. 2003 Nov 17;11(23):4941-4.

PMID:
14604655
45.

Age-related susceptibility and resistance to Plasmodium berghei in mice and rats.

Pierrot C, Adam E, Lafitte S, Godin C, Dive D, Capron M, Khalife J.

Exp Parasitol. 2003 May-Jun;104(1-2):81-5. No abstract available.

PMID:
12932766
46.

Synthesis of ferroquine enantiomers: first investigation of effects of metallocenic chirality upon antimalarial activity and cytotoxicity.

Delhaes L, Biot C, Berry L, Delcourt P, Maciejewski LA, Camus D, Brocard JS, Dive D.

Chembiochem. 2002 May 3;3(5):418-23.

PMID:
12007175
47.

Biochemical and electron paramagnetic resonance study of the iron superoxide dismutase from Plasmodium falciparum.

Gratepanche S, Ménage S, Touati D, Wintjens R, Delplace P, Fontecave M, Masset A, Camus D, Dive D.

Mol Biochem Parasitol. 2002 Apr 9;120(2):237-46.

PMID:
11897129
48.

In vitro and in vivo antimalarial activity of ferrochloroquine, a ferrocenyl analogue of chloroquine against chloroquine-resistant malaria parasites.

Delhaes L, Abessolo H, Biot C, Berry L, Delcourt P, Maciejewski L, Brocard J, Camus D, Dive D.

Parasitol Res. 2001 Mar;87(3):239-44.

PMID:
11293573
49.

Novel ferrocenic artemisinin derivatives: synthesis, in vitro antimalarial activity and affinity of binding with ferroprotoporphyrin IX.

Delhaes L, Blot C, Berry L, Maciejewski LA, Camus D, Brocard JS, Dive D.

Bioorg Med Chem. 2000 Dec;8(12):2739-45.

PMID:
11131165
50.

Use of cartilage grafts for closure of cleft palate fistulae.

Jeffery SL, Boorman JG, Dive DC.

Br J Plast Surg. 2000 Oct;53(7):551-4.

PMID:
11000068

Supplemental Content

Support Center